WO2010073011A3 - Composés utiles comme médicaments - Google Patents
Composés utiles comme médicaments Download PDFInfo
- Publication number
- WO2010073011A3 WO2010073011A3 PCT/GB2009/002945 GB2009002945W WO2010073011A3 WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3 GB 2009002945 W GB2009002945 W GB 2009002945W WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heterocyclic compounds
- ampk activators
- ampk
- compounds
- cardioprotection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
La présente invention concerne des composés de formule I dans laquelle les lignes pointillées, X, T, G, N, Y, A1 à A5 et D1 à D5 prennent les significations données dans la description. Ces composés sont utiles dans le traitement d'états ou de troubles améliorés par l'activation de l'AMPK, par exemple les maladies de la peau, les maladies pulmonaires, l'obésité, la dégénérescence maculaire liée à l'âge de type sec, la cardioprotection ou, de préférence, l'hyperinsulinémie, le diabète, le cancer, la fibrose, les maladies neurodégénératives, les dysfonctionnements sexuels, l'insuffisance cardiaque, l'inflammation et l'ostéoporose.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19377408P | 2008-12-23 | 2008-12-23 | |
US61/193,774 | 2008-12-23 | ||
US20208409P | 2009-01-27 | 2009-01-27 | |
US61/202,084 | 2009-01-27 | ||
US20287909P | 2009-04-15 | 2009-04-15 | |
US61/202,879 | 2009-04-15 | ||
US24146309P | 2009-09-11 | 2009-09-11 | |
US61/241,463 | 2009-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010073011A2 WO2010073011A2 (fr) | 2010-07-01 |
WO2010073011A3 true WO2010073011A3 (fr) | 2010-09-23 |
Family
ID=42061073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/002945 WO2010073011A2 (fr) | 2008-12-23 | 2009-12-22 | Composés utiles comme médicaments |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010073011A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CN108578682B (zh) * | 2018-07-13 | 2022-04-12 | 浙江省医学科学院 | 艾塞那肽在制备用于治疗肺纤维化的药物中的应用 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013003467A2 (fr) | 2011-06-27 | 2013-01-03 | Massachusetts Eye And Ear Infirmary | Procédés de traitement de troubles inflammatoires oculaires |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
CN103467417B (zh) * | 2012-06-07 | 2015-05-20 | 中国科学院上海药物研究所 | 牛蒡子苷元碳酰胺衍生物及其制备方法、包含该衍生物的组合物、及其用途 |
US8877980B2 (en) * | 2012-09-11 | 2014-11-04 | Al-Urdonia Lemudaddat Al-Ajsam Co. | Phenylboronic acid |
MX2015011445A (es) | 2013-03-15 | 2016-04-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina. |
JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ampkを活性化させるインダゾール化合物 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015103480A1 (fr) | 2014-01-02 | 2015-07-09 | Massachusetts Eye & Ear Infirmary | Traitement de la néovascularisation oculaire |
NZ727818A (en) | 2014-06-03 | 2020-06-26 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
MX367519B (es) | 2014-09-15 | 2019-08-26 | Idorsia Pharmaceuticals Ltd | Compuestos triazolicos como bloqueadores de canales de calcio tipo t. |
CN108699107B (zh) * | 2015-12-24 | 2022-05-10 | 加利福尼亚大学董事会 | Cftr调节剂及其使用方法 |
JP6755778B2 (ja) * | 2016-11-11 | 2020-09-16 | 花王株式会社 | PPARα活性化剤 |
MX2019007117A (es) | 2016-12-16 | 2019-09-16 | Idorsia Pharmaceuticals Ltd | Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t. |
MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
WO2019070709A1 (fr) * | 2017-10-02 | 2019-04-11 | The Regents Of The University Of California | Composés pour le traitement ou la prévention d'infections à flavivirus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103980A1 (fr) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i |
WO2005085220A1 (fr) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Utilisation de derives de thiadiazole-uree |
WO2007002461A1 (fr) * | 2005-06-23 | 2007-01-04 | Dr. Reddy's Laboratories Ltd. | Thiazoles substitués en 3,4 en tant qu'activateurs de l'ampk |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2511371A (en) | 1945-03-12 | 1950-06-13 | Monsanto Chemicals | Sulfa derivatives of 2-amino-5-alkenyl-1, 3, 4-thiadiazoles |
US2524729A (en) | 1945-03-12 | 1950-10-03 | Monsanto Chemicals | 2-amino-5-benzyl-1, 3, 4-thiadiazole and acid salts thereof |
US2420434A (en) | 1945-03-12 | 1947-05-13 | Monsanto Chemicals | 2-amino-5-alkenyl-1, 3, 4 thiadiazoles and process for making the same |
US3720685A (en) | 1970-07-15 | 1973-03-13 | Squibb & Sons Inc | 3-amino-5-benzyl-1,2,4-oxadiazoles |
US4054665A (en) | 1974-11-29 | 1977-10-18 | Sandoz, Inc. | 2-Amino-5-(trifluoromethylphenylalkyl)-1,3,4 thiadiazoles used in the treatment of insomnia and anxiety |
CH602685A5 (fr) | 1975-12-01 | 1978-07-31 | Merck Patent Gmbh | |
DE2611965A1 (de) | 1976-03-20 | 1977-09-29 | Merck Patent Gmbh | Verfahren zur herstellung von 1,3,4- thiadiazol-5-thiolen |
JP3258771B2 (ja) | 1992-11-16 | 2002-02-18 | 株式会社豊田製作所 | ブレーキロータの面振れ測定用治具 |
WO2004004720A1 (fr) | 2002-07-03 | 2004-01-15 | Astex Technology Limited | 3-(hetero) arylmethoxy pyridines et leurs analogues en tant qu'inhibiteurs de la p38 map kinase |
WO2005002673A1 (fr) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Inhibiteurs de raf kinase |
US7262020B2 (en) | 2003-07-03 | 2007-08-28 | The Regents Of The University Of California | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol |
CA2610196A1 (fr) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
EA200800302A1 (ru) | 2005-07-21 | 2008-08-29 | Бетагенон Аб | Применение производных и аналогов тиазола при лечении рака |
US7754773B2 (en) | 2005-10-06 | 2010-07-13 | University Of Massachusetts | Composition and synthesis of new reagents for inhibition of HIV replication |
WO2008029266A1 (fr) | 2006-09-08 | 2008-03-13 | Glenmark Pharmaceuticals S.A. | Inhibiteurs de la stéaroyl coa désaturase |
US20080182851A1 (en) | 2006-11-20 | 2008-07-31 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
JP2010520162A (ja) | 2007-02-28 | 2010-06-10 | スミスクライン ビーチャム コーポレーション | ステアロイル−CoAデサチュラーゼ阻害剤であるチアジアゾール誘導体 |
-
2009
- 2009-12-22 WO PCT/GB2009/002945 patent/WO2010073011A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103980A1 (fr) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i |
WO2005085220A1 (fr) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Utilisation de derives de thiadiazole-uree |
WO2007002461A1 (fr) * | 2005-06-23 | 2007-01-04 | Dr. Reddy's Laboratories Ltd. | Thiazoles substitués en 3,4 en tant qu'activateurs de l'ampk |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Non-Patent Citations (1)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2009, GOLDFARB, DAVID SCOTT: "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", XP002593929, retrieved from STN Database accession no. 2009:846107 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CN108578682B (zh) * | 2018-07-13 | 2022-04-12 | 浙江省医学科学院 | 艾塞那肽在制备用于治疗肺纤维化的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2010073011A2 (fr) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010073011A3 (fr) | Composés utiles comme médicaments | |
WO2010066684A3 (fr) | Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci | |
WO2010114824A8 (fr) | Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation | |
WO2008001195A3 (fr) | Nouveaux procédés de synthèse d'inhibiteurs de dpp iv | |
WO2012016186A8 (fr) | Inhibiteurs de kinases macrocycliques et leurs utilisations | |
PL2150530T3 (pl) | Podstawione pochodne sulfonamidu | |
WO2008094992A3 (fr) | Inhibiteurs de kinase | |
WO2007048801A3 (fr) | Medicaments augmentant le desir sexuel comprenant des derives de benzimidazolone | |
MY156530A (en) | Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators | |
WO2009155527A3 (fr) | Inhibiteurs de phosphatidylinositol 3 kinase | |
WO2012149157A3 (fr) | Composés hétérocycliques pour l'inhibition de pask | |
WO2009011871A3 (fr) | Thiadiazoles modulateurs de l'activité de pkb | |
WO2008091540A3 (fr) | Modulateurs de tgr5 et leurs procédés d'utilisation | |
TNSN07431A1 (en) | Imidazoquinolines as lipid kinase inhibitors | |
WO2010141796A3 (fr) | Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine | |
WO2010080756A3 (fr) | Dérivés d'harmine pour réduire la masse corporelle | |
WO2009120660A3 (fr) | Pyridoxazines substituées | |
WO2007009724A3 (fr) | Derives de pyrazoline substitues cycloalkane, fabrication et utilisation comme medicaments | |
WO2009121939A3 (fr) | Composés c-aryl glycosides pour le traitement du diabète et de l'obésité | |
EP2826472A3 (fr) | Composés d'activation de la télomérase et leur utilisation | |
WO2008010061A3 (fr) | 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation | |
WO2011025982A3 (fr) | Composés tétracycline | |
EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 | |
WO2009003719A3 (fr) | Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments | |
WO2007104485A3 (fr) | Composés imidazo[2,1-b]thiazole substitués et utilisation dans la fabrication de médicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09801242 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09801242 Country of ref document: EP Kind code of ref document: A2 |